| When major U.S. stock indices plunged into bear territory in 2022, big pharma stocks quickly became an oasis for nervous investors in many cases because of their largely recession-proof business models, solid cash flows, and steady quarterly dividends. Our Analysis:
As long as the price is below 46.50, follow the recommendations below: - Time frame: D1
- Recommendation: short position
- Entry point: 43.99
- Take Profit 1: 42.50
- Take Profit 2: 40.00
Alternative scenario:
If the level of 46.50 is broken-out, follow the recommendations below: - Time frame: D1
- Recommendation: long position
- Entry point: 46.00
- Take Profit 1: 48.00
- Take Profit 2: 50.00
| 
No comments:
Post a Comment